Clinical Trials Directory

Trials / Terminated

TerminatedNCT00961714

OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture

Evaluation of Safety and Effectiveness of the OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Alphatec Spine, Inc. · Industry
Sex
All
Age
50 Years – 105 Years
Healthy volunteers
Accepted

Summary

The OsseoFix Spinal Fracture Reduction System facilitates the treatment of spinal fractures by providing internal fixation and stabilization using a titanium implant in conjunction with OsseoFix+™ polymethylmethacrylate (PMMA) bone cement. The purpose of the study is to provide reasonable assurance on safety and effectiveness of the OsseoFix Spinal Fracture Reduction System for market release approval in the US. This investigational device is intended to restore biomechanical integrity to a vertebral body that has suffered a painful compression fracture in the thoracic or lumbar spine between levels T6 and L5.

Detailed description

This is a prospective, multi-center clinical study designed to evaluate safety and effectiveness of the OsseoFix Spinal Fracture Reduction System used with PMMA bone cement relative to the clinical expectations for treatment of vertebral compression fractures (VCFs). The study will be conducted at up to 15 investigational centers in the United States in 115 (up to 125) subjects with one or two vertebral compression fractures between levels T6 and L5 implanted with the investigational device(s). Baseline screening will be completed to determine eligible subjects. VCFs will be confirmed by magnetic resonance imaging (MRI), or by a CT / bone scan. These diagnostic tests will be utilized to confirm that there are no retropulsed bone fragments. Subjects who meet all inclusion criteria and do not have any exclusion criteria will be scheduled to receive the OsseoFix Spinal Fracture Reduction System. Subjects that are enrolled will be implanted with the OsseoFix Spinal Fracture Reduction System through a postero-lateral approach to the anterior vertebral body using instruments specifically designed for this procedure. Radiographs will be taken at each follow-up visit, including baseline and post-operatively. Subject's perception of pain will be assessed using the Visual Analogue Scale (VAS). Functional outcomes will be measured using the Oswestry Disability Index (ODI) and Short Form- 36 (SF-36) questionnaires as well as their neurologic status. The VAS, ODI, SF-36 and neurologic status will be measured at baseline, 4-week, 3-month, 6-month and 12-month follow-up visits. Overall patient-satisfaction will be evaluated at all post-implant scheduled follow-up visits. Adverse event will be the recorded in all scheduled and non-scheduled visits. The endpoint analysis will be performed and submitted when all implanted subjects have completed their 12-months follow-up.

Conditions

Interventions

TypeNameDescription
DEVICEOsseoFix Spinal Fracture Reduction SystemAll enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.

Timeline

Start date
2009-08-01
Primary completion
2012-12-01
Completion
2013-07-01
First posted
2009-08-19
Last updated
2022-04-28
Results posted
2022-04-04

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00961714. Inclusion in this directory is not an endorsement.